UTI vaccine
A UTI vaccine is a vaccine used for prevention of urinary tract infections (UTIs).[1][2] A number of UTI vaccines have been developed and/or marketed, including Uromune (MV-140), UroVaxom (OM-89), Solco-Urovac, and ExPEC4 V.[1][2]
Background[edit]
Recurrent urinary tract infections (UTIs) are common in women, causing significant physical and emotional distress. While antibiotics are widely used to treat them, the recurrence of UTIs poses a significant challenge. Long-term antibiotic use not only poses health risks but also contributes to the growing problem of antibiotic resistance, making effective treatment more challenging.
MV140[edit]
MV140, also known as Uromune, is a vaccine developed to treat recurrent UTIs that is made from heat-inactivated bacteria mixed with in glycerol, sodium chloride, artificial pineapple flavoring, and water.[3] It contains specific strains of four types of bacteria: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris.
This vaccine is taken by spraying it under the tongue twice a day for three months. It is currently being tested in clinical trials. Studies suggest that MV140 works by stimulating the immune system to produce antibodies and activate certain immune cells, which help protect against UTIs.
In a conducted study involving 89 individuals with a history of urinary tract infections (UTIs), participants were instructed to use two sprays of the vaccine daily for three months. Preliminary results presented at the European Association of Urology Congress in Paris revealed that nine years later, 54 percent of the participants remained free from UTIs. Women in the study remained UTI-free for approximately 4.5 years on average, while men experienced around 3.5 years without UTIs.[4] Dr. Bob Yang, who co-led the study and serves as a consultant urologist at the Royal Berkshire NHS Foundation Trust in the United Kingdom, noted that before receiving the vaccine, all participants had struggled with recurrent UTIs, which can be challenging to treat.
Current limitation[edit]
Currently, the vaccine remains in the experimental stage and waits approval from the U.S. Food and Drug Administration (FDA).
References[edit]
- ^ a b Nickel JC, Saz-Leal P, Doiron RC (August 2020). "Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future". Can Urol Assoc J. 14 (8): 281–287. doi:10.5489/cuaj.6690. PMC 7402698. PMID 33626320.
- ^ a b Prattley S, Geraghty R, Moore M, Somani BK (May 2020). "Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review". Eur Urol Focus. 6 (3): 593–604. doi:10.1016/j.euf.2019.11.002. PMID 31806578.
- ^ Nickel, J. Curtis; Doiron, R. Christopher (21 February 2023). "An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women". Pathogens. 12 (3): 359. doi:10.3390/pathogens12030359. PMC 10052183. PMID 36986281.
- ^ Rapaport, Lisa (April 11, 2024). "Experimental Uti Vaccine Offers Potential Alternative to Antibiotics". Everyday Health. Retrieved 6 May 2024.
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |